Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Añadir filtros

Tipo del documento
Intervalo de año
1.
Caspian Journal of Neurological Sciences ; 8(1):33-38, 2022.
Artículo en Inglés | EMBASE | ID: covidwho-20233199

RESUMEN

Background: Guillain-Barre Syndrome (GBS) is an autoimmune disease that may occur after infections.As Coronavirus Disease 2019 (COVID-19) may bring about GBS, it is important to assess the effect of the COVID-19 pandemic on this diseaseObjectives: This study aimed to compare the distribution and characteristics of GBS during and before theCOVID-19 pandemic in an academic referral hospital in the north of Iran.Materials & Methods: This retrospective study assessed GBS distribution and characteristics during theCOVID-19 pandemic period (from March 2020 to the end of February 2021) and before the pandemic(from March 2019 to the end of February 2020) on 5340 patients referred to the Neurology Ward ofPoursina Hospital of Guilan Province, in Iran. Result(s): There was no significant difference between GBS distribution during (0.03%) and before (0.04%)the COVID-19 pandemic (P=0.413). There were also no differences between the two periods regardingthe gender (P=0.659) and age (P=0.417) of the patients. The most common subtype of GBS during theCOVID-19 pandemic was Acute Motor and Sensory Axonal Neuropathy (AMSAN) (71.4%). In bothperiods, the most common type of treatment was intravenous administration of immune globulin. Therewas no significant difference between the two periods (P=0.838) regarding the patients' treatment response. Conclusion(s): The distribution of GBS, its subtypes, type of treatment, and response to treatment were notdifferent between the two study periodsCopyright © 2018 The Authors. This is an open access article under the CC-By-NC license

2.
Caspian Journal of Neurological Sciences ; 8(1):33-38, 2022.
Artículo en Inglés | Scopus | ID: covidwho-1675627

RESUMEN

Background: Guillain-Barré Syndrome (GBS) is an autoimmune disease that may occur after infections.As Coronavirus Disease 2019 (COVID-19) may bring about GBS, it is important to assess the effect of the COVID-19 pandemic on this diseaseObjectives: This study aimed to compare the distribution and characteristics of GBS during and before theCOVID-19 pandemic in an academic referral hospital in the north of Iran.Materials & Methods: This retrospective study assessed GBS distribution and characteristics during theCOVID-19 pandemic period (from March 2020 to the end of February 2021) and before the pandemic(from March 2019 to the end of February 2020) on 5340 patients referred to the Neurology Ward ofPoursina Hospital of Guilan Province, in Iran.Results: There was no significant difference between GBS distribution during (0.03%) and before (0.04%)the COVID-19 pandemic (P=0.413). There were also no differences between the two periods regardingthe gender (P=0.659) and age (P=0.417) of the patients. The most common subtype of GBS during theCOVID-19 pandemic was Acute Motor and Sensory Axonal Neuropathy (AMSAN) (71.4%). In bothperiods, the most common type of treatment was intravenous administration of immune globulin. Therewas no significant difference between the two periods (P=0.838) regarding the patients’ treatment response.Conclusion: The distribution of GBS, its subtypes, type of treatment, and response to treatment were notdifferent between the two study periods © 2018 The Authors. This is an open access article under the CC-By-NC license

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA